BREAST CANCER

During a Case-Based Roundtable® event, Igor Makhlin, MD, discussed with participants their impressions of datopotamab deruxtecan as therapy for patients with HR-positive, HER2-negative breast cancer, and the sequential use of multiple antibody-drug conjugates.

Erika Hamilton, MD, discussed findings from the phase 1b/2 ELECTRA study investigating a new oral combination therapy for patients with metastatic breast cancer.

A phase 1 trial is underway to assess the safety and efficacy of BTX-9341, a novel investigational oral degrader of CDK4/6 in HR-positive/HER2-negative breast cancer.

In a live virtual event, Aditya Bardia, MD, MPH, discussed the treatment landscape for patients with advanced invasive breast cancer.

In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.

The FDA approved Tepylute, a ready-to-dilute formulation of an existing treatment for breast and ovarian adenocarcinoma.

Recent approvals herald novel strategies for addressing advanced or metastatic breast cancer with ESR1 mutations.

Tanya Gupta, MD, highlighted the approved indications for antibody-drug conjugates in breast cancer, the efficacy data supporting their approvals, and ongoing studies to advance the space further.

During a Case-Based Roundtable® event, Timothy J. Pluard, MD, explores datopotamab deruxtecan as an option in hormone receptor–positive, HER2-negative breast cancer in the second article of a 2-part series.

Capivasertib combined with paclitaxel failed to improve overall survival in a phase 3 trial CAPItello-290 in metastatic triple-negative breast cancer, missing the study’s dual primary end points.

During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed biomarker testing and treatment exposure for a patient with metastatic breast cancer in the second article of a 2-part series.

Erika P. Hamilton, MD, and the Oncology Brothers review exciting data from DESTINY-Breast06 and discuss its impact on the evolving treatment landscape.

Medical oncologists discuss the INAVO120 study, which is evaluating inavolisib combination therapy in patients with PIK3CA-mutated breast cancer.

The Oncology Brothers and Erika P. Hamilton, MD, discuss the postMONARCH study investigating fulvestrant alone vs fulvestrant plus abemaciclib.

Following ASCO 2024, Erika P. Hamilton, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to review recent updates from the RxPONDER trial investigating the use of AMH levels in premenopausal women.

In separate, virtual live events, Sarah Sammons, MD, and Ruth O’Regan, MD, discussed molecular profiling and therapeutic options for a patient with advanced breast cancer after multiple lines of therapy.

During a Case-Based Roundtable® event, Ruth M. O'Regan, MD, looks at options for a patients with hormone receptor–positive, HER2-negative breast cancer and an ESR1 mutation in the second article of a 2-part series.

Trastuzumab deruxtecan therapy led to superior PFS vs chemotherapy in pretreated, HR-positive, HER2-low metastatic breast cancer as well as ‘ultralow’ disease with IHC 0 and membrane staining.

A retrospective study revealed outcomes of sequencing the 2 antibody-drug conjugates trastuzumab deruxtecan and sacituzumab govitecan in patients with metastatic breast cancer.

Progression-free survival was numerically improved with pembrolizumab plus sacituzumab govitecan vs sacituzumab govitecan alone in patients with HR-positive, HER2-negative metastatic breast cancer.

Data from the phase 3 INAVO120 trial support the priority review granted by the FDA to inavolisib, palbociclib, and fulvestrant for the treatment of PIK3CA-mutated breast cancer.

Pembrolizumab combined with chemotherapy significantly improved overall survival in patients with high-risk early triple-negative breast cancer, according to the prespecified interim analysis of the phase 3 KEYNOTE-522 trial.

Data from the phase 3 INAVO120 trial support the breakthrough therapy designation granted by the FDA to inavolisib, palbociclib, and fulvestrant for the treatment of PIK3CA-mutated breast cancer.

Gabriel N. Hortabagyi, MD, FACP, provides an overview of the phase 3 NATALEE trial evaluating the combination of ribociclib with endocrine therapy as adjuvant treatment in patients with hormone receptor-positive/HER2-negative early breast cancer.

During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed multiple later-line treatment options in hormone receptor–positive breast cancer with participants in the first article of a 2-part series.

Halle Moore, MD, discusses some of the main concerns that patients with breast cancer have about fertility after treatment.

Findings from a phase 1b/2 study support the continued development of palazestrant plus ribociclib for patients with estrogen receptor-positive/HER2-negative metastatic breast cancer.

With the clearance of an investigational new drug application for BTX-9341 from the FDA, a phase 1 trial will evaluate the agent in HR-positive/HER2-negative breast cancer.

During a Case-Based Roundtable® event, Ruth M. O'Regan, MD, led a discussion on whether to order next-generation sequencing and/or circulating tumor DNA testing for a patient with hormone receptor–positive breast cancer after progression in the first article of a 2-part series.

Finalized breast cancer screening recommendations from the United States Preventive Services Task Force suggest women aged 40 to 74 should get a mammogram every other year.